MWA
CRSP icon

Medallion Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Medallion Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.19K Hold
88
– – ﹤0.01% 910
2025
Q4 		$4.62K Sell
88
-36
-29% -$2.16K ﹤0.01% 871
2025
Q3 		$8.04K Hold
124
– – ﹤0.01% 786
2025
Q2 		$6.01K Hold
124
– – ﹤0.01% 806
2025
Q1 		$4.11K Hold
124
– – ﹤0.01% 821
2024
Q4 		$4.88K Buy
+124
New +$5.86K ﹤0.01% 750

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Medallion Wealth Advisors's CRSP Position: Q1 2026 in Review

Medallion Wealth Advisors held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 88 shares worth $4.19K. The position accounts for ﹤0.01% of the portfolio, ranked #910.

Medallion Wealth Advisors first reported a position in CRSP in Q4 2024 and has held it in 6 quarters since. The position peaked at $8.04K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Medallion Wealth Advisors held 88 shares of CRISPR Therapeutics worth $4.19K as of Q1 2026.
  • Medallion Wealth Advisors left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Medallion Wealth Advisors's portfolio in Q1 2026, its #910 holding.
  • Medallion Wealth Advisors first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Medallion Wealth Advisors's CRISPR Therapeutics position peaked at $8.04K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Medallion Wealth Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.